Search Results - "Chebli, J M F"

Onychomycosis in Inflammatory Bowel Diseases by Gaburri, D, Chebli, JMF, Zanine, A, Gamonal, AC, Gaburri, PD

“…Background  As far as we have sought for in Medline and PubMed, not one study until now has evaluated the prevalence of onychomycosis in patients with…”
Get full text

Gastrointestinal: Whipple's disease by Coli, MV, Chebli, JMF, Gaburri, PD

Get full text

Colonic ulcers in propylthiouracil induced vasculitis with secondary antiphospholipid syndrome by Gaburri, P D, Chebli, J M F, Attalla, Â, Pereira, C M N, Bonfante, H L, Martins Junior, E V, Gaburri, A K

“…A 48 year old white woman was admitted to the hospital because of several bouts of migratory polyarthritis, weight loss, fever, and abdominal pain over a…”
Get full text

P558 Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naïve Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational Study by Ferreira, S, Chebli, J M F, Parra, R, Yukie Sassaki, L, de Mello, M K, Luporini, R L, Chebli, L A, Firmino Nóbrega, F J, da Silva, B C, Dutra, R D M, de Oliveira Vasconcelos, J R, Moraes Sales, M P, Féres, O, Parente, J M L, Troncon, L E D A

“…Abstract Background Vedolizumab (VDZ) and infliximab (IFX), are considered first-line agents in the treatment of moderate to severe Ulcerative Colitis (UC)…”
Get full text

P698 Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentre Real-World Observational Study by Parra, R, Chebli, J M F, Freitas Cardoso de Azevedo, M, Chebli, L A, Zabot, G P, Cassol, O S, Fróes, R D S B, Santana, G O, Lubini, M, Magro, D O, Imbrizi, M, Moraes, A C S, Teixeira, F V, Alves Jr, A J T, Gasparetti Junior, N L T, Ferreira, S D C, Queiroz, N S F, Kotze, P G, Féres, O

“…Abstract Background Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking in Latin America. In this…”
Get full text

P373 Primary sclerosing cholangitis associated with inflammatory bowel disease: clinical characteristics of patients from reference centers in Brazil by da Silva, B C, Chebli, J M F, Ferreira, S D C, Chebli, L A, Evangelista, R K A, Ribeiro, T C D R, Alencar, S R, Borges, M D M, Lima, G A S, Rzetelna, H, Freire, C C F, Parente, J M L

“…Abstract Background Inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) are closely associated pathological entities that, when present…”
Get full text

P586 Vedolizumab in Mild to Moderate Crohn’s Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study by Dotti, A Z, Vilela, E G, Chebli, J M F, Chebli, L A, Magro, D O, Steinwurz, F, Argollo, M, Carvalho, N S, Parente, J M L, Parra, R S, Perin, R L, Flores, C, Morsoletto, E M, Ferreira, S D C, Ludvig, J C, Kaiser Jr, R L, Queiroz, N S F, Faria, M A G, Nicollelli, G M, Andrade, A R, Kotze, P G

“…Abstract Background Vedolizumab, a human monoclonal antibody that blocks integrin α4-β7, was approved for the management of Inflammatory Bowel Diseases. In…”
Get full text

P746 Real-world Effectiveness and Safety of Advanced Combination Therapy in Patients with Inflammatory Bowel Disease: A Multi-center Brazilian Study by Feitosa, F C, Queiroz, N S F, Parra, R S, Azevedo, M F C D, Schiavetti, B L P, Flores, C, Fróes, R D S B, Boarini, L R, Boratto, S D F, Junior, A J T A, Junior, N L T G, Nóbrega, F J F, Teixeira, E F L, Rzetelna, H, Damião, A O M C, Motta, M P, Sassaki, L Y, Souza, H S P D, Luporini, R L, Ferreira, S D C F, Chebli, L A, Chebli, J M F

“…Abstract Background Advanced Combination Therapy (ACT) involves the concurrent use of biologic agents and/or small molecules and is a viable consideration for…”
Get full text

Physical Activity in Hemodialysis Patients Measured by Triaxial Accelerometer by Paula, Rogério Baumgratz de, Pinheiro, Bruno do Valle, Chebli, J. M. F., Oliveira, Julio César Abreu de, Filho, Gilberto Francisco Ferreira, Carvalho, Laís Fernanda Caldi d’Ornellas, Teixeira, Daniel Rodrigues, Carvalho, Erich Vidal, Reboredo, Maycon Moura, Gomes, Edimar Pedrosa, Sanders-Pinheiro, Helady

“…Different factors can contribute to a sedentary lifestyle among hemodialysis (HD) patients, including the period they spend on dialysis. The aim of this study…”
Get full text

P460 Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil by Parra, R S, Feitosa, M R, Féres, O, Ribeiro da Rocha, J J, Chebli, J M F, Chebli, L, Bertges, E R, Gomes, T N F, Ambrogini Jr, O, Alves Junior, A J T, Lubini, M

“…Abstract Background Ustekinumab (UST) is a fully human monoclonal antibody against IL-12/23. UST induced a clinical response and maintained a higher rate of…”
Get full text

Anemia in Inflammatory Bowel Disease Outpatients: Prevalence, Risk Factors, and Etiology by Chebli, J. M. F., Castro, Antonio Carlos Santana, Reboredo, Maycon Moura, Pinheiro, Bruno do Valle, Moutinho, Ivana Lúcia Damásio, Chebli, Liliana Andrade, Nascimento, Cristiano Rodrigo de Alvarenga, Hallack Neto, Abrahão Elias, Antunes, Carla Valéria de Alvarenga, Malaguti, Carla

“…Anemia is common in inflammatory bowel disease (IBD). However, epidemiological studies of nonwestern IBD populations are limited and may be confounded by…”
Get full text

Education and imaging. Gastrointestinal: Whipple's disease by Coli, M V, Chebli, J M F, Gaburri, P D

Get full text